1 Baylor College of Medicine, Texas Medical Center, Houston.
2 University of Maryland School of Medicine, Baltimore.
J Manag Care Spec Pharm. 2017 Apr;23(4-a Suppl):S10-S19. doi: 10.18553/jmcp.2017.23.4-a.s10.
Virtual panel meetings were conducted among 7 physicians, all of whom are independent experts, including 3 nephrologists, 2 cardiologists, and 2 emergency medicine physicians (the panel). The panel met with the purpose of discussing the current treatment landscape, treatment challenges, economic impact, and gaps in care for patients with hyperkalemia that is associated with heart failure and chronic kidney disease. The stated goal of the panel discussion was to develop practical solutions in the identification and management of hyperkalemia in this patient population. The panel noted that hyperkalemia is a serious condition that can lead to life-threatening complications, yet the treatment paradigm for hyperkalemia has remained without major advances for approximately 50 years, until the approval of patiromer. A number of issues still exist in the management of this patient population, including the lack of uniform treatment guidelines and consensus regarding the approach to treatment. As part of its effort, the panel developed an algorithm, the Proposed Diagnostic Algorithm for Hyperkalemia Treatment in the Acute Care Setting/Chronic Care. The panel agreed that patiromer appears to be a viable option for the management of hyperkalemia in patients with chronic kidney disease and/or heart failure and in patients who experience chronic hyperkalemia.
This panel discussion was funded by Relypsa and facilitated by Magellan Rx Management. Rafique is a principal investigator for Relypsa and serves as a consultant for Instrumentation Laboratory, Magellan Health, Relypsa, and ZS-Pharma. Butler serves as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CardioCell, Janssen, Merck, Novartis, Relypsa, and ZS-Pharma. Lopes and Farnum are employed by Magellan Rx Management. Rafique designed the management protocol for this panel discussion and contributed to the writing and editing of this report document. The other authors report no conflicting interests. Relypsa is the manufacturer of Veltassa (patiromer).
讨论心力衰竭和慢性肾脏病伴发高钾血症患者的治疗现状、治疗挑战、经济影响和护理缺口，旨在为该患者人群中高钾血症的识别和管理制定实用的解决方案。
虚拟小组会议在 7 名医生（均为独立专家，包括 3 名肾病专家、2 名心脏病专家和 2 名急诊医学专家）中进行。小组会议的目的是讨论心力衰竭和慢性肾脏病伴发高钾血症患者的治疗现状、治疗挑战、经济影响和护理缺口，旨在为该患者人群中高钾血症的识别和管理制定实用的解决方案。小组会议指出，高钾血症是一种严重的病症，可导致危及生命的并发症，但高钾血症的治疗模式在大约 50 年的时间里没有重大进展，直到 patiromer 的批准。该患者人群的治疗仍存在许多问题，包括缺乏统一的治疗指南以及对治疗方法的共识。
作为其努力的一部分，小组制定了一个算法，即急性治疗环境/慢性治疗中高钾血症治疗的拟议诊断算法。小组认为，对于慢性肾脏病和/或心力衰竭伴发高钾血症的患者以及慢性高钾血症患者，patiromer 似乎是一种可行的选择。
本次小组讨论由 Relypsa 资助，由 Magellan Rx Management 协助进行。Rafique 是 Relypsa 的主要研究者，并担任 Instrumentation Laboratory、Magellan Health、Relypsa 和 ZS-Pharma 的顾问。Butler 担任 Amgen、AstraZeneca、Bayer、Boehringer Ingelheim、CardioCell、Janssen、Merck、Novartis、Relypsa 和 ZS-Pharma 的顾问。Lopes 和 Farnum 受雇于 Magellan Rx Management。Rafique 为本次小组讨论设计了管理方案，并参与了本报告文件的编写和编辑。其他作者报告无利益冲突。Relypsa 是 Veltassa（patiromer）的制造商。
